Brought to you by:
Powered by wagescape.com
Labor Market Pulse
Texarkana, TX-Texarkana, AR Metro Edition
Focus: LIFE SCI
Texarkana's thin life sciences bench meets Houston's hiring pull.
4.70%
Texarkana unemployment rate
vs 4.40% one year earlier
56.2%
Texas pharma establishment growth
since 2019, outpacing local talent pipeline
$8.8B combined
Houston biomanufacturing investment
Eli Lilly + Bristol Myers Squibb, Generation Park
$61,619
Texarkana Health Care/Social Assistance avg wage
25.1% of tracked metro sector employment
This Month's Takeaways
Texarkana's labor slack is deepening, but talent isn't deep to begin with.
Unemployment moved from 4.40% to 4.70% year-over-year, yet the metro's life sciences-relevant workforce is concentrated in a small health care base rather than a broad biotech bench. A looser headline labor market does not translate into looser specialized-talent supply here.
Houston's manufacturing buildout is a regional retention risk, not just a Houston story.
Eli Lilly and Bristol Myers Squibb's combined $8.8B in Generation Park investment creates over 600 new jobs competing statewide for quality and operations talent. Texarkana employers should treat these announcements as a recruiting threat to existing staff, not a distant market development.
Regulatory affairs scarcity reaches even thin regional markets.
National VP Regulatory Affairs compensation of $320K-$580K reflects an acute, structural shortage rather than a cyclical blip tied to GLP-1 and faster FDA pathway demands. Smaller metros without deep regulatory benches may need to benchmark against national, not local, compensation data to retain scarce expertise.
Pipeline investment is underway, but it won't close the gap fast.
San Jacinto College's NIBRT-licensed biotech training center, the only one in the southern U.S., signals state-level recognition of the technician shortage. Texarkana-area employers likely won't see meaningful graduate flow for several hiring cycles, making near-term retention strategy more urgent than pipeline-dependent workforce planning.
Local Labor Conditions
Texarkana's unemployment rate climbed to 4.70% in the most recent reading, up from 4.40% a year earlier, even as the metro's small Health Care and Social Assistance base — 7,546 workers at an average $61,619 wage — continues to anchor local life sciences-adjacent employment. Statewide biomanufacturing expansion (Eli Lilly's $6.5B Houston project, Bristol Myers Squibb's $2.3B facility) is pulling skilled operators and quality talent toward major metros, leaving smaller markets like Texarkana more exposed to outmigration of credentialed talent than to direct competition for new facility jobs.
Leadership & Talent Implications
Rising metro unemployment alongside a thin, concentrated local talent base means Texarkana-area life sciences employers compete less on volume and more on being the only credible regional option for specialized clinical, quality, and regulatory talent — losing even a handful of staff to Houston or Dallas-area manufacturing buildouts can materially strain headcount plans. With Texas pharma establishment growth running at 56.2% since 2019 against a still-undersupplied technician and regulatory pipeline, build-vs-outsource decisions for clinical and quality functions may increasingly favor CRO partnerships over local hires who are difficult to replace quickly. Consider reviewing retention compensation for regulatory and quality roles against statewide rather than purely metro-level pay data, given how readily qualified staff can be drawn toward Houston-area biomanufacturing expansion.
